ROCHESTER, N.Y., Oct. 12 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , a leading developer of image-based biomarker solutions, announced today that Edward Ashton, chief scientific officer, will present key results related to imaging system quality assurance for clinical trials at the upcoming Drug Information Association (DIA) medical imaging workshop, to be held October 12th - 13th at the Renaissance Washington, DC Hotel. The data to be presented, which demonstrates the importance of VirtualScopics' proprietary imaging phantoms and site qualification system, will be part of an expert panel discussion entitled, "Implementation of Imaging in Clinical Trials."
The DIA workshop entitled, "Medical Imaging Conference Critical Path Opportunities List: From Opportunities to Action," will explore key medical imaging issues drawn from the Federal Drug Administration's (FDA) Critical Path Opportunities List. The workshop objective is to identify action items to advance these imaging opportunities as tools to modernize drug development. Specific opportunities for applying imaging in drug development will be addressed, focusing on the current state of qualification and what is needed to advance the modality as a biomarker or surrogate endpoint.
"The data in our presentation shows that implementing a quantitative imaging component in a clinical trial without strict quality controls, beyond what are provided by the device manufacturers, is likely to result in a great deal of wasted time and money with no real return," said Dr. Ashton.
"Being asked to present on an expert panel at this premier event is continued validation of the role we are playing in the acceleration of drug development, one of the most prominent issues facing the pharmaceutical industry and the focus of the critical path initiative," said Jeff Markin, president and CEO of VirtualScopics.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit http://www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Bagatelle-Black Public Relations, 661/263-1842 tracy@bagatelleblack.com Tim Ryan Trout Group Investor Relations 212-477-9007 x 24 tryan@troutgroup.com
VirtualScopics, Inc.CONTACT: Tracy Bagatelle-Black of Bagatelle-Black Public Relations,+1-661-263-1842, or tracy@bagatelleblack.com; or Tim Ryan of Trout GroupInvestor Relations, +1-212-477-9007, ext. 24, or tryan@troutgroup.com, bothfor VirtualScopics, Inc.
Web site: http://www.virtualscopics.com/
